FDA Approves Remicade for Treatment of Ankylosing Spondylitis

The U.S. Food and Drug Administration has approved Remicade to treat the signs and symptoms of active ankylosing spondylitis, a progressive inflammatory condition of the spine which can result in fusion of the spinal vertebrae and structural damage to hips and other joints. Read the press release. This is the second approval for Remicade within the last three months. Recently, Remicade in combination with methotrexate was approved for use as first-line therapy for patients with moderately active to severely active rheumatoid arthritis.

Related Resources:

• The Facts of Remicade
• More About Ankylosing Spondylitis
• Guide to Low Back Pain
• Ankylosing Spondylitis Screening Quiz